Applied Therapeutics (APLT)

• Market cap: $55.5M
• 1 day: -1.73%
• 5 days: 18.73%
• 1 month: -24.11%
• 3 months: -31.38%
• 6 months: -95.46%
• Year to date: -56.38%
• 1 year: -90.91%
• 5 years: -98.94%
• 10 years: -95.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Employees: 35

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

72% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 25

47% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $969K

0.74% more ownership

Funds ownership: 98.15% [Q3] → 98.89% (+0.74%) [Q4]

6% less funds holding

Funds holding: 125 [Q3] → 118 (-7) [Q4]

13% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 45

50% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]

90% less capital invested

Capital invested by funds: $961M [Q3] → $98.5M (-$862M) [Q4]